Recommendations:
1.
Annually Urinary albumin (spot albumin-to-creatinine ratio) & GFR.
2.
Those with eGFR ≥ 30, SGLT2-i may lower renal & CV risk
3. In CKD & increased risk for CV events, GLP-1 agonists may lower risk for albuminuria progression & or CV events

